Low doses in immunotherapy: Are they effective?

Checkpoint inhibitors are versatile immunomodulatory agents, and they are being approved for the treatment of an increasing number of cancers, based on the demonstration of clinical benefits. While they have changed the landscape of treatment of many cancers, they remain inaccessible to most patient...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research, statistics, and treatment (Online) statistics, and treatment (Online), 2019-01, Vol.2 (1), p.54-60
Main Authors: Vijay M Patil, Vanita Noronha, Amit Joshi, Anuja Abhyankar, Nandini Menon, Shripad Banavali, Sudeep Gupta, Kumar Prabhash
Format: Article
Language:English
Subjects:
accessibility
biologically effective dose
checkpoint inhibitor
financial toxicity
immunotherapy
low dose
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Checkpoint inhibitors are versatile immunomodulatory agents, and they are being approved for the treatment of an increasing number of cancers, based on the demonstration of clinical benefits. While they have changed the landscape of treatment of many cancers, they remain inaccessible to most patients, especially in low-income countries because of their prohibitive costs. Conventionally, chemotherapy drug doses are decided based on the maximum tolerable dose in phase 1 studies, but this dose-finding methodology is not applicable to targeted therapies where dose-limiting toxicity is not reached at doses much higher than sufficiently active doses. This review article focuses on how lower doses of immunotherapy drugs could be as efficacious as the currently recommended doses, thus decreasing the financial burden.
ISSN:2590-3233
2590-3225
DOI:10.4103/CRST.CRST_29_19